Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28933613 | 0.98 | PTGS1 (0.51) | PTGS1PTGS2APPMETTL3ALDH1A3 | |
| SCHEMBL21033157 | 0.88 | ALDH1A3 (0.60) | PTGS1PTGS2APPALDH1A3USP30 | |
| SCHEMBL21947017 | 0.86 | APP (0.51) | PTGS1PTGS2APPMETTL3ALDH1A3 | |
| SCHEMBL1733059 | 0.84 | PTGS1 (0.53) | PTGS1PTGS2APPMETTL3USP30 | |
| SCHEMBL2087277 | 0.84 | METTL3 (0.47) | PTGS1PTGS2APPMETTL3ALDH1A3 | |
| SCHEMBL24247758 | 0.82 | APP (0.48) | APPMETTL3ALDH1A3USP30CSNK1D | |
| SCHEMBL20646999 | 0.82 | APP (0.48) | PTGS1PTGS2APPMETTL3ALDH1A3 | |
| SCHEMBL20646997 | 0.82 | CSNK1D (0.48) | PTGS1PTGS2APPMETTL3ALDH1A3 | |
| SCHEMBL3367812 | 0.81 | NPC1 (0.64) | METTL3USP30KDM4EEGLN1ROCK2 | |
| SCHEMBL1638034 | 0.80 | KDM4E (0.61) | APPMETTL3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4563146-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-06-04 | — | — | EP | disclosed |
| CN-111349093-B | 5, 6-bicyclic compounds as WNT signal pathway inhibitors and medical application thereof | 汇瀚医疗科技有限公司 | 2021-07-02 | — | — | CN | disclosed |
| CN-111349093-A | 5, 6-bicyclic compounds as WNT signal pathway inhibitors and medical application thereof | 汇瀚医疗科技有限公司 | 2020-06-30 | — | — | CN | disclosed |
| WO-2020125759-A1 | COMPOUND AS WNT SIGNAL PATHWAY INHIBITOR AND MEDICAL USE THEREOF | 汇瀚医疗科技有限公司 | 2020-06-25 | — | — | WO | disclosed |
| WO-2020125759-A1 | COMPOUND AS WNT SIGNAL PATHWAY INHIBITOR AND MEDICAL USE THEREOF | 汇瀚医疗科技有限公司 | 2020-06-25 | — | — | WO | disclosed |
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012006203-A1 | N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| EP-2225243-B1 | Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-11-16 | — | — | EP | disclosed |
| EP-2225243-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZOÝL,2- A¨PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009106751-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[L,2- A]PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | PTGS1 384/4885PTGS2 482/4885APP 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.